Basepoint Wealth’s Immunome IMNM Stock Holding History

Basepoint Wealth’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.99K	Hold	91	–	–	﹤0.01%	535
2025 Q4	$1.95K	Buy	+91	New	+$1.6K	﹤0.01%	522

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Basepoint Wealth's IMNM Position: Q1 2026 in Review

Basepoint Wealth held its Immunome (IMNM) position steady in Q1 2026 at 91 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #535.

Basepoint Wealth first reported a position in IMNM in Q4 2025 and has held it in 2 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

Basepoint Wealth held 91 shares of Immunome worth $1.99K as of Q1 2026.
Basepoint Wealth left its Immunome share count unchanged in Q1 2026.
Immunome made up ﹤0.01% of Basepoint Wealth's portfolio in Q1 2026, its #535 holding.
Basepoint Wealth first reported a position in Immunome in Q4 2025 and has held it in 2 quarters since.
200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Basepoint Wealth's 13F filing for Q1 2026, filed 7 May 2026.